P300, clinical symptoms, and neuropsychological parameters in acute and remitted schizophrenia: A preliminary report

Eikmeier, G.; Lodemann, E.; Zerbin, Dieter; Gastpar, Markus

doi:10.1016/0006-3223(92)90100-e

Cited by 48 publications

(22 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It appears, nevertheless, plausible that normal latency is a valid finding. Prolonged P300 latency is not consistent with the study of Eikmeier et al [ 15] on schizophrenics in remission who also had a small P300 latency; however, the criterion of remission used was a decrease in Brief Psychiatric Rating Scale scores from 50 ± 7 to 31 ± 7, which may not reflect a true remission. The duration of remission in the present study ranged from 4 to 72 months (24.71 ± 24.5) and is a potential source of varia tion.…”

Section: Discussioncontrasting

confidence: 47%

See 1 more Smart Citation

Smaller Auditory P300 Amplitude in Schizophrenics in Remission

et al. 1995

View full text Add to dashboard Cite

The P300 event-related potential (ERP) was recorded using the auditory oddball paradigm in 12 (6 male) schizophrenic (DSM-IIIR) patients in rigorously defined clinical remission. The ERP was also recorded in 10 (5 male) age-, sex-and education-matched control subjects. ERP latencies and amplitude were measured at Cz and Pz recording sites. Mean latencies of the P300 in schizophrenic patients in remission at Cz [343.6 ±31 (SD) ms] and Pz (346.15 ± 30 ms) did not differ from those of normals (Cz: 332.8 ± 23 ms, Pz: 323 ± 38 ms). The P300 ERP amplitude was significantly (p < 0.05) smaller in schizophrenics in remission at both Cz (9.2 ± 4.4 µV) and Pz (8.8 ± 4.4 µV) than in normals (Cz: 13.3 ± 2.90 µV; Pz: 12.71 ± 4.18 µV). The significance of the smaller auditory P300 amplitude in schizophrenia is discussed.

show abstract

Section: Discussioncontrasting

confidence: 47%

“…One of the methods to validate this claim would be to demonstrate these abnormalities in schizophrenics after complete remission. In earlier stud ies on schizophrenics in remission, the remission criteria were not very rigid [15]. This study examined P300 in schizophrenics who were in rigorously defined and stable clinical remission.…”

Section: Introductionmentioning

confidence: 99%

Smaller Auditory P300 Amplitude in Schizophrenics in Remission

et al. 1995

View full text Add to dashboard Cite

show abstract

“…The relationship between auditory P300 and clinical symptoms has been established repeatedly in cross-sectional studies, especially for negative symptoms~Eikmeier, Lodemann, Zerbin, & Gastpar, 1992;Ford et al, 1999a;Mathalon, Ford, & Pfefferbaum, 1999a;McCarley et al, 1991;McConaghy et al, 1993;Pfefferbaum, Ford, Roth, & Kopell, 1980;Pfefferbaum et al, 1989;Turetsky et al, 1998;Ward, Catts, Fox, Michie, & McConaghy, 1991!. We reported that patients with more negative symptoms had smaller amplitude auditory and visual P300s~Figure 6!, even though the visual P300 was not significantly smaller in patients with schizophrenia~Pfefferbaum et al, 1989!. Fewer studies~e.g., Egan et al, 1994;McCarley et al, 1993;O'Donnell et al, 1993!…”

Section: Clinical Contributions To Broken P300mentioning

confidence: 55%

Schizophrenia: The broken P300 and beyond

1999

View full text Add to dashboard Cite

Many of the social, economic, and political problems facing people with schizophrenia are due to a misconception in the community that schizophrenia is not a biologically based disease but a myth. Because the diagnosis is based on self‐reported symptoms, it is difficult for many people to acknowledge that schizophrenia is real. One goal of psychophysiological research has been to anchor both diagnosis and symptoms in biological reality. Reduction of the amplitude of the P300 component of the event‐related potential (ERP) is the most replicable biological marker of the disease. Data are presented suggesting that P300 is both a state and a trait marker of the disease and may be sensitive to the progressive/degenerative course of the disease. Although the P300 tracks changes in clinical symptoms, it remains reduced even in patients in relative remission. P300 amplitude reduction is related to enduring negative symptoms, waning of attention, and gray matter volume deficits. ERP components other than P300 can also manifest the biological reality of various symptoms of the disease.

show abstract

“…However, during typical antipsychotic treatment, the N100 amplitude was similar among the three genotype groups (table 1). In addition, most studies suggested that treatment with typical antipsychotics has no significant effects on deficient auditory ERPs in schizophrenia [7][8][9]. Taking these together, the second explanation is less likely.…”

Section: Discussionmentioning

confidence: 90%

“…Many studies have shown a reduction in the auditory P300, N200 and N100 amplitude in schizophrenia relative to controls [6]. Most of the studies reported that treatment with typical antipsychotics has no significant effects on deficient auditory ERPs in schizophrenia [7][8][9]. However, one recent report demonstrated that clozapine treatment might increase the deficient amplitude, especially the P300 [10].…”

Section: Introductionmentioning

confidence: 99%

Evidence for an Association between Polymorphism in the Serotonin-2A Receptor Variant (102T/C) and Increment of N100Am plitude in Schizophrenics Treated with Clozapine

Tsai

Yang

et al. 2001

Neuropsychobiology

View full text Add to dashboard Cite

Using event-related potentials (ERPs), a reduction in the auditory N100, N200 and P300 amplitude has been found in schizophrenic patients and may represent some pathophysiological deficit. Therefore, we investigated whether the genetic variant of the serotonin-2A receptor is associated with ERP change after clozapine treatment in schizophrenic patients. Ninety-nine schizophrenic patients were included in the study. The results demonstrated that patients with 102C/C genotype have higher N100 amplitude than other patients after clozapine treatment. Our findings suggested that serotonin-2A receptor polymorphism may relate to clozapine response in schizophrenic patients. An objective and reliable tool like ERPs to assess patients’ treatment response may afford more consistent results in pharmacogenetic studies.

show abstract

P300, clinical symptoms, and neuropsychological parameters in acute and remitted schizophrenia: A preliminary report

Cited by 48 publications

References 11 publications

Smaller Auditory P300 Amplitude in Schizophrenics in Remission

Smaller Auditory P300 Amplitude in Schizophrenics in Remission

Schizophrenia: The broken P300 and beyond

Evidence for an Association between Polymorphism in the Serotonin-2A Receptor Variant (102T/C) and Increment of N100Am plitude in Schizophrenics Treated with Clozapine

Contact Info

Product

Resources

About